World's Best Scientists 2026 revealed!
Geremia B. Bolli

Geremia B. Bolli

D-Index & Metrics

Medicine

D-Index
83
Citations
22576
World Ranking
15727
National Ranking
615

Overview

Geremia B. Bolli is affiliated with the University of Perugia in Italy and has contributed extensively to the field of diabetes research and metabolism. Their work spans multiple subfields including endocrinology, diabetes and metabolism, surgery, molecular biology, genetics, and physiology, reflecting a broad and interdisciplinary approach to medical science.

The main areas of study for Geremia B. Bolli focus on diabetes management and research, diabetes treatment and management, pancreatic function and diabetes, metabolism related to diabetes and cancer, diabetes and associated disorders, as well as hyperglycemia and glycemic control in critically ill and hospitalized patients. Pharmacology and obesity treatment also feature among their interests.

Frequent publication venues for their research include:

  • Diabetes Obesity and Metabolism
  • Diabetes Care
  • Diabetes Research and Clinical Practice
  • il Diabete
  • Diabetes

Geremia B. Bolli has collaborated with several co-authors across their publications, including:

  • Carmine G. Fanelli
  • Francesca Porcellati
  • Paola Lucidi
  • David R. Owens
  • Brian M. Frier

Some of their recent papers include:

  • Insulin: evolution of insulin formulations and their application in clinical practice over 100 years, 2022, Acta Diabetologica
  • C-peptide determination in the diagnosis of type of diabetes and its management: A clinical perspective, 2022, Diabetes Obesity and Metabolism
  • The continuing quest for better subcutaneously administered prandial insulins: a review of recent developments and potential clinical implications, 2020, Diabetes Obesity and Metabolism
  • Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial, 2020, Diabetes Obesity and Metabolism
  • Lower risk of severe hypoglycaemia with insulin glargine 300 U/mL versus glargine 100 U/mL in participants with type 1 diabetes: A meta-analysis of 6-month phase 3 clinical trials, 2020, Diabetes Obesity and Metabolism

Best Publications

  • Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

    M Lepore;S Pampanelli;C Fanelli;F Porcellati

  • Abnormal Glucose Counterregulation in Insulin-dependent Diabetes Mellitus: Interaction of Anti-Insulin Antibodies and Impaired Glucagon and Epinephrine Secretion

    Bolli G;de Feo P;Compagnucci P;Cartechini Mg

  • Alternative routes of insulin delivery

    D. R. Owens;B. Zinman;G. Bolli

  • Hypoglycemia, Diabetes, and Cardiovascular Events

    Cyrus V. Desouza;Geremia B. Bolli;Vivian Fonseca

  • Insulins today and beyond

    David R Owens;Bernard Zinman;Geremia B Bolli

  • Insulin analogues and their potential in the management of diabetes mellitus.

    G. B. Bolli;R. D. Di Marchi;G. D. Park;S. Pramming

  • New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1)

    Matthew C. Riddle;Geremia B. Bolli;Monika Ziemen;Isabel Muehlen-Bartmer

  • New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)

    G B Bolli;M C Riddle;R M Bergenstal;M Ziemen

  • Diabetes and breast cancer risk: a meta-analysis

    P. Boyle;M. Boniol;A. Koechlin;C. Robertson

  • Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus

    Paolo Gresele;Giuseppe Guglielmini;Massimiliano De Angelis;Silvia Ciferri

  • Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial

    R P L M Hoogma;P J Hammond;R Gomis;D Kerr

  • Acute Antihyperglycemic Mechanisms of Metformin in NIDDM: Evidence for Suppression of Lipid Oxidation and Hepatic Glucose Production

    Gabriele Perriello;Paolo Misericordia;Elena Volpi;Antonella Santucci

  • The “Dawn Phenomenon” — A Common Occurrence in Both Non-Insulin-Dependent and Insulin-Dependent Diabetes Mellitus

    Geremia B. Bolli;John E. Gerich

  • Insulin is required for prandial ghrelin suppression in humans.

    Giuseppe Murdolo;Paola Lucidi;Chiara Di Loreto;Natascia Parlanti

  • Pathogenesis of the dawn phenomenon in patients with insulin-dependent diabetes mellitus. Accelerated glucose production and impaired glucose utilization due to nocturnal surges in growth hormone secretion.

    Peter J. Campbell;Geremia B. Bolli;Philip E. Cryer;John E. Gerich

  • Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study.

    Francesca Porcellati;Paolo Rossetti;Natalia Ricci Busciantella;Stefania Marzotti

  • Patient‐level meta‐analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes

    R. Ritzel;R. Roussel;R. Roussel;G. B. Bolli;L. Vinet

  • Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime.

    C Lalli;M Ciofetta;P Del Sindaco;E Torlone

  • Reversibility of unawareness of hypoglycemia in patients with insulinomas.

    A. Mitrakou;C. Fanelli;T. Veneman;G. Perriello

  • Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24‐week, randomized, double‐blind study

    G. Bolli;Francesco Dotta;E. Rochotte;S. E. Cohen

Frequent Co-Authors

Philip Home
Philip Home Newcastle University
Julio Rosenstock
Julio Rosenstock The University of Texas Southwestern Medical Center
David R. Owens
David R. Owens Cardiff University
Hannele Yki-Järvinen
Hannele Yki-Järvinen University of Helsinki
Angelo Avogaro
Angelo Avogaro University of Padua
Chris Robertson
Chris Robertson University of Strathclyde
Peter Boyle
Peter Boyle University of Edinburgh
Philippe Autier
Philippe Autier University of Strathclyde
John E. Gerich
John E. Gerich Mayo Clinic

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're interested in health care professions beyond traditional medical school, there are several flexible online pathways worth considering. Online nursing programs now offer accessible options for students seeking to enter or advance in the nursing field without relocating or taking a career break.

For those already licensed as registered nurses (RNs), the most affordable accredited online rn to bsn programs can help you earn a Bachelor of Science in Nursing quickly and efficiently. This can open doors to advanced practice, leadership, and specialized clinical roles.

Looking to specialize further or enter academia? Consider pursuing phd nursing programs online. These doctorates equip nurses for teaching and high-level research positions in universities or healthcare organizations.

For those with bachelor's degrees in other fields, online direct entry msn programs for non-nurses provide a streamlined route into advanced nursing, even for those without a nursing background. Explore your options with online nursing programs and chart your ideal career pathway in healthcare.

Best Scientists Citing Geremia B. Bolli

Trending Scientists